Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finasteride for prevention of SIRS after PCNL lithotripsy
IRCT20190624043991N31Phase 3Recruiting
- Sponsor
- Tehran University of Medical Sciences
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of finasteride in nephrolithiasis (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Systemic inflammatory response syndrome (SIRS). Started Dec 2025; status: recruiting.
02
Drugs
finasteride
03
Conditions
nephrolithiasis
Beyond the preview
Go deeper on IRCT20190624043991N31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190624043991N31.